This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Key PointsRTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter.The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW Investments, LP.Apellis now represents 1.93% of portfolio AUM, which places it outside the fund's top five holdings.10 stocks we like better than Apellis Pharmaceuticals › RTW Investments initiated a new stake in …